M62I (p.Met62Ile) variant of ACE2 (Angiotensin-converting enzyme 2)
M62I (p.Met62Ile) in ACE2 (Angiotensin-converting enzyme 2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.39 / 1. The record also includes population frequency data, experimental measurements, and structural context.
M62I (p.Met62Ile) variant details
- p.Met62Ile
- NCI-TCGA TCGA novel
- Ensembl rs1928149922
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.391
- REVEL 0.17
- CADD 25.20
- PolyPhen-2 0.42
- SIFT 0.02
- UniProt: Variant assessed as somatic; moderate impact.
- Most common in the Finnish in Finland (FIN) population (allele frequency 0.00019)
- Structural context available
- ACE2 binding to SARS-CoV-2 spike protein, low affinity: score -0.246